Adjunctive therapy for glucose control in patients with type 1 diabetes

References

• American Diabetes Association Standards of medical care in diabetes-2017 Diabetes Care 2017 40 S1 S135 27979885
   PubMed Web of Science ®Google Scholar
• Frandsen CS Dejgaard TF Madsbad S Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus Lancet Diabetes Endocrinol 2016 4 9 766 780 26969516
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group Nathan DM Genuth S The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 1993 329 14 977 986 8366922
   PubMed Web of Science ®Google Scholar
• Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC study 30-year follow-up Diabetes Care 2016 39 5 686 693 26861924
   PubMed Web of Science ®Google Scholar
• Livingstone R Boyle JG Petrie JR REMOVAL Study Team A new perspective on metformin therapy in type 1 diabetes Diabetologia 2017 60 9 1594 1600 28770327
   PubMed Web of Science ®Google Scholar
• AstraZeneca Pharmaceuticals, Symlin (pramlintide acetate) injection [package insert] Wilmington, DE, USA 2016
   Google Scholar
• Miller KM Foster NC Beck RW Current state of type 1 diabetes treatment in the US: updated data from the T1D exchange clinic registry Diabetes Care 2015 38 6 971 978 25998289
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb, Glucophage (metformin hydrochloride) [package insert] Princeton NJ, USA 2017
   Google Scholar
• Whitehouse F Kruger DF Fineman M A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes Diabetes Care 2002 25 4 724 730 11919132
   PubMed Web of Science ®Google Scholar
• Ratner RE Dickey R Fineman M Amylin replacement with pramlintide as an adjunct to insulin therapy improved long-term glycemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial Diabet Med 2004 21 11 1204 1212 15498087
   PubMed Web of Science ®Google Scholar
• Ratner R Whitehouse F Fineman MS Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain in patients with type 1 diabetes approaching glycemic targets Exp Clin Endocrinol Diabetes 2005 113 4 199 204 15891954
   PubMed Web of Science ®Google Scholar
• Edelman S Garg S Frias J A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes Diabetes Care 2006 29 10 2189 2195 17003291
   PubMed Web of Science ®Google Scholar
• Marrero DG Crean J Zhang B Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes Diabetes Care 2007 30 2 210 216 17259483
   PubMed Web of Science ®Google Scholar
• Levetan C Want LL Weyer C Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps Diabetes Care 2003 26 1 1 8 12502651
   PubMed Web of Science ®Google Scholar
• Kruger DF Aronoff SL Edelman SV Through the looking glass: current and future perspective on the role of hormonal interplay in glucose homeostasis Diabetes Educ 2007 33 Suppl 2 32S 46S 17483531
   PubMed Web of Science ®Google Scholar
• Hieronymus L Griffin S Role of amylin in type 1 and type 2 diabetes Diabetes Educ 2015 41 Suppl 1 47S 56S 26424675
   PubMed Web of Science ®Google Scholar
• Purnell JQ Hokanson JE Marcovina SM Steffes MW Cleary PA Brunzell JD Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure JAMA 1998 280 2 140 146 9669786
   PubMed Web of Science ®Google Scholar
• Ryan G Briscoe TA Jobe L Review of pramlintide as adjunctive therapy in treatment of type and type 2 diabetes Drug Des Devel Ther 2008 2 203 214
   Google Scholar
• Staels F Moyson C Mathieu C Metformin as add-on to intensive insulin therapy in type 1 diabetes mellitus Diabetes Obes Metab 2017 19 10 1463 1467 28318105
   PubMed Web of Science ®Google Scholar
• Lund SS Tarnow L Astrup AS Effect of metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study PLoS One 2008 3 10 e3363 18852875
   PubMed Web of Science ®Google Scholar
• Meyer L Bohme P Delbachian I The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients Diabetes Care 2002 25 12 2153 2158 12453953
   PubMed Web of Science ®Google Scholar
• Khan AS McLoughney CR Ahmed AB The effect of metformin on blood glucose control in overweight patients with type 1 diabetes Diabet Med 2006 23 10 1079 1084 16978371
   PubMed Web of Science ®Google Scholar
• Jacobsen IB Henriksen JE Beck-Nielsen H The effect of metformin in overweight patients with type 1 diabetes and poor metabolic control Basic Clin Pharmacol Toxicol 2009 105 3 145 149 19496776
   PubMed Web of Science ®Google Scholar
• Petrie JR Chaturvedi N Ford I Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomized, placebo-controlled trial 2017 5 8 597 609
   Google Scholar
• Hamilton J Cummings E Zdravkovic V Finegood D Daneman D Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance Diabetes Care 2003 26 1 138 143 12502670
   PubMed Web of Science ®Google Scholar
• Särnblad S Kroon M Aman J Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomised placebo-controlled trial with aspects on insulin sensitivity Eur J Endocrinol 2003 149 4 323 329 14514347
   PubMed Web of Science ®Google Scholar
• Nadeau KJ Chow K Alam S Effects of low dose metformin in adolescents with type 1 diabetes mellitus: a randomized, double-blinded placebo-controlled study Pediatr Diabetes 2015 16 3 196 203 24698216
   PubMed Web of Science ®Google Scholar
• Libman IM Miller KM DiMeglio LA T1D Exchange Clinic Network Metformin RCT Study Group Effect of metformin added to insulin on glycemic control among overweight/obese adolescents with type 1 diabetes a randomized clinical trial JAMA 2015 314 21 2241 2250 26624824
   PubMed Web of Science ®Google Scholar
• Nwosu BU Maranda L Cullen K A randomized, double-blind, placebo-controlled trial of adjunctive metformin therapy in overweight/obese youth with type 1 diabetes PLoS One 2015 10 9 e0137525 26367281
   PubMed Web of Science ®Google Scholar
• Kielgast U Holst JJ Madsbad S Treatment of type 1 diabetic patients with glucagon-like peptide (GLP-1) and GLP-1R agonists Curr Diabetes Rev 2009 5 4 266 275 19925391
   PubMedGoogle Scholar
• Garber AJ Abrahamson MJ Barzilay JI Consensus statement by the American association of clinical endocrinologists and american college of endocrinology on the comprehensive type 2 diabetes management algorithm – 2017 executive summary Endocr Pract 2017 23 2 207 238 28095040
   PubMed Web of Science ®Google Scholar
• Unger J Rationale use of GLP-1 receptor agonists in patients with type 1 diabetes Curr Diab Rep 2013 13 5 663 668 23955813
   PubMed Web of Science ®Google Scholar
• Hari Kumar KV Shaikh A Prusty P Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study Diabetes Res Clin Pract 2013 100 2 e55 e58 23490599
   PubMed Web of Science ®Google Scholar
• Griffin KJ Thompson PA Gottschalk M Kyllo JH Rabinovitch A Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabets (REPAIR-T1D): 12 month results of a multicentre, randomised, placebo-controlled, phase 2 trial Lancet Diabetes Endocrinol 2014 2 9 710 718 24997559
   PubMed Web of Science ®Google Scholar
• Rother KI Spain LM Wesley RA Effects of exenatide alone and in combination with daclizumab on β-cell function in long-standing type 1 diabetes Diabetes Care 2009 32 12 2251 2257 19808924
   PubMed Web of Science ®Google Scholar
• Sarkar G Alattar M Brown R Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes Diabetes Care 2014 37 3 666 670 24194508
   PubMed Web of Science ®Google Scholar
• Varanasi A Bellini N Rawal D Liraglutide as additional treatment for type 1 diabetes Eur J Endocrinol 2011 165 1 77 84 21646283
   PubMed Web of Science ®Google Scholar
• Harrison LB Mora PF Clark GO Lingvay I Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs J Investig Med 2013 61 1 40 44
   PubMed Web of Science ®Google Scholar
• Traina AN Lull ME Hui AC Zahorian TM Lyons-Patterson J Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patient receiving continuous subcutaneous insulin infusion therapy Can J Diabetes 2014 38 4 269 272 24797495
   PubMed Web of Science ®Google Scholar
• Farngren J Persson M Schweizer A Foley JE Ahren B Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counter-regulation during hypoglycemia in type 1 diabetes J Clin Endocrinol Metab 2012 97 10 3799 3806 22855332
   PubMed Web of Science ®Google Scholar
• Garg SK Moser EG Bode BW Effect of sitagliptin on postprandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial Endocr Pract 2013 19 1 19 28 23186950
   PubMed Web of Science ®Google Scholar
• Schopman JE Hoekstra JB Frier BM Effects of sitagliptin on counter-regulatory and incretin hormones during acute hypoglycaemia in patient with type 1 diabetes: a randomized double-blind placebo-controlled crossover study Diabetes Obes Metab 2015 17 6 546 553 25694217
   PubMed Web of Science ®Google Scholar
• Ellis SL Moser EG Snell-Gerbeon JK Rodionova AS Hazenfield RM Garg SK Effect of sitagliptin on glucose control in adult patients with type 1 diabetes: a pilot, double-blind, randomized, crossover trial Diabet Med 2011 28 10 1176 1181 21923696
   PubMed Web of Science ®Google Scholar
• Giampietro O Giampietro C Bartola LD Masoni MC Matteucci E Sitagliptin as add-on therapy in insulin-deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes Drug Des Devel Ther 2013 7 99 104
   Web of Science ®Google Scholar
• Guo H Fang C Huang Y Pei Y Chen L Hu J The efficacy and safety of DPP4 inhibitors in patients with type 1 diabetes: a systematic review and meta-analysis Diabetes Res Clin Pract 2016 121 184 191 27741478
   PubMed Web of Science ®Google Scholar
• Kielgast U Krarup T Holst JJ Madsbad S Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function Diabetes Care 2011 34 7 1463 1468 21593296
   PubMed Web of Science ®Google Scholar
• Kuhadiya ND Dhindsa S Ghanim H Addition of liraglutide to insulin in patients with type 1 diabetes: a randomized placebo-controlled clinical trial of 12 weeks Diabetes Care 2016 39 6 1027 1035 27208343
   PubMed Web of Science ®Google Scholar
• Frandsen CS Dejgaard TF Holst JJ Andersen HU Thorsteinsson B Madsbad S Twelve-week treatment with liraglutide as add-on to insulin in normal-weight patients with poorly controlled type 1 diabetes: a randomized, placebo-controlled, double-blind parallel study Diabetes Care 2015 38 12 2250 2257 26486191
   PubMed Web of Science ®Google Scholar
• Mathieu C Zinman B Hemmingsson JU Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial Diabetes Care 2016 39 10 1702 1710 27506222
   PubMed Web of Science ®Google Scholar
• Ahren B Hirsch IB Pieber TR Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the ADJUNCT TWO randomized trial Diabetes Care 2016 39 10 1693 1701 27493132
   PubMed Web of Science ®Google Scholar
• Kuhadiya ND Malik R Bellini NJ Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus Endocr Pract 2013 19 6 963 967 23807520
   PubMed Web of Science ®Google Scholar
• Dejgaard TF Frandsen CS Hansen TS Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomized, double-blind, placebo-controlled trial Lancet Diabetes Endocrinol 2016 4 3 221 232 26656289
   PubMed Web of Science ®Google Scholar
• Raman VS Mason KJ Rodriguez LM The role of adjunctive exenatide therapy in pediatric type 1 diabetes Diabetes Care 2010 33 6 1294 1296 20332358
   PubMed Web of Science ®Google Scholar
• Renukuntla VS Ramchandani N Trast J Cantwell M Heptulla RA Role of glucagon-like peptide-1 anaglogue versus amylin as adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm J Diabetes Sci Technol 2014 8 5 1011 1017 25030181
   PubMedGoogle Scholar
• Sherr JL Patel NS Michaud CI Mitigating meal-related glycemic excursions in an insulin-sparing manner during closed-loop insulin delivery: the beneficial effects of adjunctive pramlintide and liraglutide Diabets Care 2016 39 7 1127 1134
   PubMed Web of Science ®Google Scholar
• Amylin Pharmaceuticals, Inc, Byetta (exenatide) [package insert] San Diego, CA, USA 2009
   Google Scholar
• Novo Nordisk A/S, Inc, Victoza (liraglutide) [package insert] Bagsvaerd, Denmark 2017
   Google Scholar
• Bode BW Garg SK The emerging role of adjunctive noninsulin anti-hyperglycemic therapy in the management of type 1 diabetes Endocr Pract 2016 22 2 220 230 26484403
   PubMed Web of Science ®Google Scholar
• Sands AT Zambrowicz BP Rosenstock J Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes Diabetes Care 2015 38 7 1181 1188 26049551
   PubMed Web of Science ®Google Scholar
• Neal B Perkovic V Mahaffey KW CANVAS Program Collaborative Group Canagliflozin and cardiovascular and renal events in type 2 diabetes N Engl J Med 2017 377 7 644 657 28605608
   PubMed Web of Science ®Google Scholar
• Zinman B Wanner C Lachin JM Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes N Engl J Med 2015 373 22 2117 2128 26378978
   PubMed Web of Science ®Google Scholar
• Henry RR Rosenstock J Edelman S Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study Diabetes Care 2015 38 3 412 419 25271207
   PubMed Web of Science ®Google Scholar
• Henry RR Thakkar P Tong C Polidori D Alba M Efficacy and safety of canagliflozin, a sodium–glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes Diabetes Care 2015 38 12 2258 2265 26486192
   PubMed Web of Science ®Google Scholar
• Peters AL Henry RR Thakkar P Tong C Alba M Diabetic ketoacidosis with canagliflozin, a sodium–glucose cotransporter 2 inhibitor, in patients with type 1 diabetes Diabetes Care 2016 39 4 532 538 26989182
   PubMed Web of Science ®Google Scholar
• Perkins BA Cherney DZ Partridge H Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial Diabetes Care 2014 37 5 1480 1483 24595630
   PubMed Web of Science ®Google Scholar
• Pieber TR Famulla S Eilbracht J Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1) Diabetes Obes Metab 2015 17 10 928 935 26080652
   PubMed Web of Science ®Google Scholar
• Garg SK Henry RR Banks P Effects of sotagliflozin added to insulin in patients with type 1 diabetes N Engl J Med 2017 377 24 2337 2348 28899222
   PubMed Web of Science ®Google Scholar
• Peters AL Buschur EO Buse JB Cohan P Diner JC Hirsch IB Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium–glucose cotransporter 2 inhibition Diabetes Care 2015 38 9 1687 1693 26078479
   PubMed Web of Science ®Google Scholar
• Fadini GP Bonora BM Avogaro A SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System Diabetologia 2017 60 8 1385 1389 28500396
   PubMed Web of Science ®Google Scholar
• Rosenstock J Ferrannini E Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors Diabetes Care 2015 38 9 1638 1642 26294774
   PubMed Web of Science ®Google Scholar
• Kuhadiya ND Ghanim H Mehta A Dapagliflozin as additional treatment to liraglutide and insulin in patients with type 1 diabetes J Clin Endocrinol Metab 2016 101 9 3506 3515 27490915
   PubMed Web of Science ®Google Scholar
• Pettus J Reeds D Cavaiola TS Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: a randomized controlled trial Diabetes Obes Metab Epub 2017 Dec 28
   Web of Science ®Google Scholar
• Pearson MJ Unger RH Holland WL Clinical trials, triumphs, and tribulations of glucagon receptor antagonists Diabetes Care 2016 39 7 1075 1077 27330122
   PubMed Web of Science ®Google Scholar